Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(66.7%)

Early Phase 1

1(33.3%)

3Total

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07261241Phase 2Not Yet Recruiting

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

Role: collaborator

NCT05037799Unknown

Dose Optimization for Rubidium PET Imaging in Patients With Known or Suspected Ischemic Heart Disease

Role: collaborator

NCT01590680Unknown

Expanded Access Protocol Using 131I-MIBG

Role: lead

NCT03561259Phase 2Unknown

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Role: lead

NCT01583842Early Phase 1Terminated

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

Role: collaborator

NCT02117284Completed

Rubidium Elution System Performance Testing

Role: collaborator

All 6 trials loaded